News Focus
News Focus
Followers 3160
Posts 967891
Boards Moderated 152
Alias Born 09/04/2000

Re: mick post# 221835

Friday, 09/04/2020 3:38:09 PM

Friday, September 04, 2020 3:38:09 PM

Post# of 246425
Pfizer Inc. (NYSE:PFE) has been a longtime favorite among investors due to its dividend. Despite being kicked off Dow Jones as it was replaced by the biotech company Amgen, Inc. (NASDAQ:AMGN), it is still one of the best bets when it comes to the COVID-19 vaccine. Yet, latest news reports that COVID-19 vaccine candidates being developed by Moderna Inc (NASDAQ:MRNA) and BioNTech SE (NASDAQ:BNTX) and Pfizer itself will require stringent standards for refrigeration. This factor could hamper how they are distributed. Unsurprisingly, stocks tumbled. On the other hand, there are about half a dozen COVID-19 vaccine candidates in clinical trials in the U.S but not all of them are mRNA vaccines. The vaccine being developed by AstraZeneca plc (NYSE:AZN) and the University of Oxford is a recombinant viral vector vaccine whereas the Inovio Pharmaceutical Inc's (NASDAQ:INO) candidate is DNA-based. Competitive positioning will be greatly influenced by storage and delivery conditions. But Pfizer has its background and precious experiences in vaccines which greatly increase its odds of success.

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today